Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Shareholder Meeting Date to Approve the Business Combination
NEW YORK and CUPERTINO, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that an Extraordinary General Meeting of Shareholders of Tenzing (the "Shareholder Meeting") to approve the pending business combination between Tenzing and Reviva (the “Business Combination”) is scheduled to be held on Tuesday, December 8, 2020, at 9:00 a.m., Eastern time. Due to COVID-19 restrictions on in-person meetings, the Shareholder Meeting will be completely virtual and conducted via live webcast.
Tenzing filed its definitive proxy statement/prospectus with respect to the Shareholder Meeting related to the Business Combination (the "Proxy Statement") with the U.S. Securities and Exchange Commission (the "SEC") on November 12, 2020 and began mailing it to Tenzing shareholders on November 13, 2020. The Proxy Statement is available on the SEC website at www.sec.gov. Holders of Tenzing's ordinary shares at the close of business on the record date of November 4, 2020 are entitled to notice of the virtual Shareholder Meeting and to vote at the virtual Shareholder Meeting.
Tenzing’s shareholders are asked to read the Proxy Statement, including, among other things, the reasons for Tenzing’s Board of Director’s unanimous recommendation that shareholders vote "FOR" the Business Combination and the other proposals set forth in the Proxy Statement.
Tenzing shareholders who need assistance in completing the proxy card, require additional copies of the proxy materials, or have questions regarding the Shareholder Meeting may contact Tenzing’s proxy solicitor, Advantage Proxy, Inc., by telephone at (877) 870-8565 (toll free) or by email at firstname.lastname@example.org.
About Tenzing Acquisition Corp.
About Reviva Pharmaceuticals, Inc.
No Offer or Solicitation
Important Information about the Business Combination and Where to Find It
Participants in Solicitation
Reviva Pharmaceuticals, Inc.
Investor Relations Contact:
#TECHSUPERSHOW Conference Party
Key Tools of the IoT Security Trade